Filtering by:
Cancer UpdatesCommon Questions About the COVID-19 Outbreak
Cancer patients, their caregivers, and others need to take precautions to lower their risk of getting COVID-19, which is caused by a type of coronavirus. Learn what you can do to help protect yourself and others.
When Should You Start Getting Screened for Colorectal Cancer?
Regular screening can find colorectal cancer when it is small, hasn’t spread, and might be easier to treat. People at average risk for colorectal cancer begin screening at age 45.
Facts & Figures 2021 Reports Another Record-Breaking 1-Year Drop in Cancer Deaths
The death rate from cancer in the United States has continued to decline. From 1991 to 2018, the cancer death rate has fallen 31%. This includes a 2.4% decline from 2017 to 2018—a new record for the largest 1-year drop in the cancer death rate. These are just some of the findings from the annual statistics reported from the American Cancer Society (ACS).
Cervical Precancers Drop Since Introduction of HPV Vaccine
A study using data from the Centers for Disease Control and Prevention (CDC) provides evidence that the human papillomavirus (HPV) vaccine is effectively reducing the numbers of cervical precancer – lesions that can become cervical cancer.
FDA Approves First Drug for Cancers with a High Tumor Mutational Burden
The US Food and Drug Administration (FDA) has expanded the approval of the immunotherapy drug pembrolizumab (Keytruda) to include any cancer with a high tumor mutational burden (TMB-H).
American Cancer Society Updates Guideline for Diet and Physical Activity
The American Cancer Society has updated its guideline on diet and physical activity for cancer prevention. Staying at a healthy weight, staying active throughout life, following a healthy eating pattern, and avoiding or limiting alcohol may greatly reduce a person's lifetime risk of developing or dying from cancer.
FDA Approves Trodelvy (Sacituzumab govitecan-hziy) for Triple Negative Breast Cancer
The US Food and Drug Administration (FDA) approved a new type of therapy for triple-negative breast cancer that has spread to other parts of the body and hasn’t responded to other treatments.
FDA Approves Pemazyre (Pemigatinib) for Bile Duct Cancer
The US Food and Drug Administration (FDA) approved the first targeted therapy for bile duct cancer. Pemazyre (pemigatinib) is for adults whose cancer has grown after at least one previous chemotherapy treatment and whose tumors have a mutation in the FGFR2 gene.